News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Arndt Vogel: First-Line Atezolizumab plus Bevacizumab for HCC in Asia-Pacific
Arndt Vogel/X
Apr 25, 2025, 12:50

Arndt Vogel: First-Line Atezolizumab plus Bevacizumab for HCC in Asia-Pacific

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology at Hannover Medical School, shared an article by Choong-kun Lee, et al. on X:

“RW Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for HCC in Asia-Pacific.

  • 1,141 pts, 55.1% 2nd line.
  • mPFS 2.9; mOS: 8 mo.
  • Lenva better compared to Sora, TKI plus ICI promising.
  • IMbrave 251 phase-3 awaited!

Arndt Vogel: First-Line Atezolizumab plus Bevacizumab for HCC in Asia-Pacific

Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries.

Authors: Choong-kun Lee, et al.

Arndt Vogel: First-Line Atezolizumab plus Bevacizumab for HCC in Asia-Pacific

Arndt Vogel Asia Pacific atezolizumab Bevacizumab cancer Choong-kun Lee fight against cancer Global fight against cancer Hannover Medical School HCC liver cancer OncoDaily Oncology
Special Coverage
Blog
May 21, 2025, 09:36
Carmen Monge-Montero: Join Webinar on Migration, Displacement and Cancer Care Access in Europe
Blog
May 21, 2025, 09:04
Sebastian Szmit: Pleasure to Present My Expertise for the Cardio-Oncology Conference at Yale New Haven Hospital
Blog
May 21, 2025, 08:51
Margaret Fitch Will Be Keynote Speaker at ONS- Nigeria Upcoming Conference
Science
May 21, 2025, 08:27
Shankar Siva: PSMA PET Sensitivity Surpasses 90% in Prostate Cancer Meta-Analysis
Science
May 21, 2025, 08:22
Vivek Subbiah: Cancer Treatment Paradigms in The Precision Medicine Era
Blog
May 21, 2025, 08:19
GAMPER Webinar June 2025: Radiobiological Aspects of Radiotherapy and the Potential for Hypofractionation
Blog
May 21, 2025, 08:19
Cathy Eng: Two of my earlyonset Colorectal Cancer patients were honored at this annual run in Owensboro
Blog
May 21, 2025, 08:07
Amy Comander: Honored to Volunteer at Roxbury Community Health Fair
Blog
May 21, 2025, 08:02
Catherine Alix-Panabières: Honored to Highlight Our Research on Liquid Biopsy at the CHU de Montpellier
Blog
May 21, 2025, 07:53
Helena Linardou: Last Chance to Vote for the IASLC Board Election by May 22
Blog
May 21, 2025, 07:32
Ruben Mesa: Grateful to Take On a New Role as Clinical Leader for Advocate Health’s National Cancer Program
Blog
May 21, 2025, 07:25
Benedikt Westphalen Shares Final ESMO Recommendations for Molecular Tumour Boards